H.R. 3042 (119th)Bill Overview

MMEDS Act of 2025

Taxation|Taxation
Cosponsors
Support
Bipartisan
Introduced
Apr 28, 2025
Discussions
Bill Text
Current stageCommittee

Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for c…

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief

Creates a new tax subchapter that gives large tax credits to medical manufacturers that locate research, production, or component production in designated "economically distressed zones".

Provides a wage/fringe/depreciation credit equal to 40% (higher for certain repatriated or population-health facilities), a purchase credit for goods/services sourced from those zones (30% arm’s-length, 5% related-party), and enhanced allowances and bonus-expensing options for specified repatriated or population-health manufacturing.

Establishes criteria and an application process for designating economically distressed census tracts, includes territories, and sets effective dates; amends public health law to define “population health products,” prioritize vulnerable populations, expand HHS strategic initiatives, require interagency delivery coordination, and require an HHS report to Congress.

Passage40/100

Targeted manufacturing incentives and public-health alignment improve prospects, but high fiscal cost, complexity, and need for inter-committee agreement reduce near-term odds.

CredibilityPartially aligned

Relative to its intended legislative type, this bill is a well-structured substantive policy change that creates targeted tax credits and amends public health statutes with clear definitions and operational elements. It specifies core mechanics, eligible activities, and administrative roles while integrating with existing statutory frameworks.

Contention62/100

Progressives emphasize jobs and vulnerable-population protections.

02 · What it does

Who stands to gain, and who may push back.

Who this appears to help vs burden50% / 50%
Targeted stakeholdersFederal agencies · Taxpayers
Likely helped
  • Targeted stakeholdersMay incentivize manufacturing jobs and investment in high-poverty census tracts.
  • Targeted stakeholdersCould strengthen domestic medical supply chains and reduce dependence on foreign suppliers.
  • Targeted stakeholdersProvides targeted support for repatriation and production of specified population health products.
Likely burdened
  • Federal agenciesLikely reduces federal tax revenue through sizable new tax expenditures.
  • TaxpayersMay create compliance complexity and administrative burden for taxpayers and Treasury.
  • Targeted stakeholdersCould encourage relocation or reshaping of corporate activity aimed at qualifying for credits.
03 · Why people split

Why the argument around this bill splits.

Progressives emphasize jobs and vulnerable-population protections.
Progressive80%

Generally supportive of using federal incentives to create jobs in high-poverty communities and to secure medical supply chains.

Views the population-health provisions positively for focusing on vulnerable groups.

Concerned about corporate capture and wants stronger labor, environmental, and access safeguards.

Leans supportive
Centrist65%

Sees pragmatic value in targeted incentives to revive manufacturing and strengthen supply chains, balanced by concerns about fiscal cost and implementation.

Wants transparent metrics, anti-abuse guardrails, and regular evaluation.

Support is conditional on oversight and accountability.

Split reaction
Conservative30%

Skeptical of targeted tax credits and expanded federal intervention in industry.

Appreciates job creation and supply-chain security goals but worries about market distortion, fiscal cost, and bureaucratic designation processes.

Likely to push for state control and fewer subsidies.

Likely resistant
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood40/100

Targeted manufacturing incentives and public-health alignment improve prospects, but high fiscal cost, complexity, and need for inter-committee agreement reduce near-term odds.

Scope and complexity
52%
Scopemoderate
52%
Complexitymedium
Why this could stall
  • No official cost estimate or offsets included in text
  • How many and which census tracts qualify under criteria
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Progressives emphasize jobs and vulnerable-population protections.

Targeted manufacturing incentives and public-health alignment improve prospects, but high fiscal cost, complexity, and need for inter-commi…

Unlocked analysis

Relative to its intended legislative type, this bill is a well-structured substantive policy change that creates targeted tax credits and amends public health statutes with clear definitions and operational elements. It…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis